2019
DOI: 10.1016/j.neuroscience.2019.10.016
|View full text |Cite
|
Sign up to set email alerts
|

Memantine Mitigates Oligodendrocyte Damage after Repetitive Mild Traumatic Brain Injury

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 70 publications
0
10
0
Order By: Relevance
“…The treatment of memantine, a low-affinity uncompetitive NMDAR antagonist without affecting normal physiological activity, attenuated anesthesia and surgery-induced overactivation of NMDARs and calpain and improved cognitive impairments in aging mice. It has been previously demonstrated that memantine is neuroprotective in various brain diseases, including AD [40], Parkinson's disease [41], traumatic brain injury [42], and paininduced cognitive impairments [43], which involves its anti-inflammation, anti-oxidation, anti-apoptosis, and anti-glutamate excitotoxicity properties. In our study, we showed that NMDAR/Ca 2+ /calpain is mechanistically involved in neuroprotective effects of memantine in anesthesia and surgery-induced cognitive impairments in aging mice.…”
Section: Discussionmentioning
confidence: 99%
“…The treatment of memantine, a low-affinity uncompetitive NMDAR antagonist without affecting normal physiological activity, attenuated anesthesia and surgery-induced overactivation of NMDARs and calpain and improved cognitive impairments in aging mice. It has been previously demonstrated that memantine is neuroprotective in various brain diseases, including AD [40], Parkinson's disease [41], traumatic brain injury [42], and paininduced cognitive impairments [43], which involves its anti-inflammation, anti-oxidation, anti-apoptosis, and anti-glutamate excitotoxicity properties. In our study, we showed that NMDAR/Ca 2+ /calpain is mechanistically involved in neuroprotective effects of memantine in anesthesia and surgery-induced cognitive impairments in aging mice.…”
Section: Discussionmentioning
confidence: 99%
“…A study focusing on comorbid blast-induced mTBI used BCI-838 (MSGS0210), a Group II metabotropic glutamate receptor (mGluR2/3) antagonist (BCI-838), which reduced PTSD-like behavior, anxiety, fearful behavior, and long-term recognition memory impairment (104). Memantine remains among treatment options, exhibiting a potential to mitigate neuropathological and behavioral outcomes in mTBI and lessen PTSD-like behavior (137)(138)(139)(140). As no FDA-approved treatments for TBI exist, this article provides a preview of opportunities for therapeutic research using preclinical modeling platforms.…”
Section: Biomarker Development and Treatment Approaches For Blast-ind...mentioning
confidence: 99%
“…A prominent cause of mitochondrial stress (and thus increased ROS formation) in neurotrauma is calcium overload via glutamate–NMDA interaction. While preliminary research focused on the broad-stroke downregulation of the NMDA receptor has proven to be counterproductive with many side effects and a limited window of therapy, research has shown that there are two NMDA receptors of interest: synaptic NMDA receptors which increase nuclear Ca 2+ and antioxidant production and extra-synaptic NMDA receptors which promote cytoplasmic Ca 2+ and mitochondrial stress [ 93 ]. Recent research has focused on the selective inhibition of extra-synaptic NMDA receptors via memantine, a well-studied neuroprotective drug in AD [ 80 , 94 ].…”
Section: Emerging Treatmentsmentioning
confidence: 99%